anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control. In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs. 

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia. 

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).

In studies assessing the effect of colesevelam on the pharmacokinetics of glipizide ER in healthy volunteers, reductions in glipizide AUC 0-∞ and C max of 12% and 13%, respectively were observed when colesevelam was coadministered with glipizide ER. When glipizide ER was administered 4 hours prior to colesevelam, there was no significant change in glipizide AUC 0-∞ or C max, -4% and 0%, respectively. Therefore, glipizide should be administered at least 4 hours prior to colesevelam to ensure that colesevelam does not reduce the absorption of glipizide.
Stress urinary incontinence (SUI) affects up to 1/3 of women and negatively impacts multiple aspects of a woman's life. Pelvic floor physical therapy has been shown to improve stress incontinence through multiple mechanisms, including rhabdosphincter hypertrophy. Yoga and Pilates have also been shown to improve stress incontinence but there is a key gap in understanding how yoga-Pilates impacts urethral function and if these exercises represent a viable option for treating SUI.

To fill this gap a new exercise is proposed: a web-based 8-week yoga-Pilates pelvic floor workout. The investigators plan to enroll women with SUI and compare urethral rhabdosphincter cross-sectional area in a pre-post intervention study. The investigators will also administer validated quality of life and severity measures for SUI to evaluate the potential efficacy of yoga-Pilates. The overarching goal of this project is to determine how yoga-Pilates impact urethral function and if these exercises decrease SUI symptoms.
FIELD: medicine. SUBSTANCE: invention relates to method of attenuation, treatment or prophylaxis of drug-mediated respiratory depression, muscle rigidity or nausea/emesis in animal associated with administration in indicated animal of the mixed delta/mu-opioid agonist or drug mediates respiratory depression. Method involves administration in animal receiving indicated drug the effective dose of compound as agonist of delta- -receptor of the formula (I)  . Method allows to reduce the indicated respiratory depression, muscle rigidity or nausea/emesis with enhanced effectiveness. EFFECT: improved methods, enhanced effectiveness of compositions. 19 cl, 2 dwg
Upon systemic S. indica colonization in split-root system cyst and root-knot nematodes benefit from endophyte-triggered carbon allocation and altered defense responses what significantly facilitates their development in A. thaliana. Serendipita indica is an endophytic fungus that establishes mutualistic relationships with different plants including Arabidopsis thaliana. It enhances host's growth and resistance to different abiotic and biotic stresses such as infestation by the cyst nematode Heterodera schachtii (CN). In this work, we show that S. indica also triggers similar direct reduction in development of the root-knot nematode Meloidogyne javanica (RKN) in A. thaliana. Further, to mimick the natural situation occurring frequently in soil where roots are unequally colonized by endophytes we used an in vitro split-root system with one half of A. thaliana root inoculated with S. indica and the other half infected with CN or RKN, respectively. Interestingly, in contrast to direct effects, systemic effects led to an increase in number of both nematodes. To elucidate this phenomenon, we focused on sugar metabolism and defense responses in systemic non-colonized roots of plants colonized by S. indica. We analyzed the expression of several SUSs and INVs as well as defense-related genes and measured sugar pools. The results show a significant downregulation of PDF1.2 as well as slightly increased sucrose levels in the non-colonized half of the root in three-chamber dish. Thus, we speculate that, in contrast to direct effects, both nematode species benefit from endophyte-triggered carbon allocation and altered defense responses in the systemic part of the root, which promotes their development. With this work, we highlight the complexity of this multilayered tripartite relationship and deliver new insights into sugar metabolism and plant defense responses during S. indica-nematode-plant interaction.
FIELD: medicine, phytotherapy. SUBSTANCE: invention proposes an agent that can be used for treatment of liver cirrhosis accompanying with ascitis. Invention proposes agent representing the herbal species comprising the following components: vegetable parsley herb, knot- grass herb, pheasant's eye herb and maize stigmas and containing additionally: common sandy immortelle, linden flowers, flax seeds, fennel fruits, garden angelica roots, Saint-John's-wort herb, centaury herb, licorice roots, sweet flag rhizome with roots, dandelion roots, madder roots, common wormwood herb, European goldenrod herb, pine buds, medicinal sweet clover herb, Iceland moss, gum-tree leaves, cowberry leaves, bearberry herb, black elder flowers, pot-marigold herb, juniper fruits, burnet roots taken in the definite ratio of components. Intake of this agent results to normalization of biochemical indices and clinical symptoms of liver cirrhosis. EFFECT: enhanced effectiveness of agent and treatment, valuable medicinal properties of species. 2 tbl, 4 ex
BACKGROUND: Growth retardation and short final height is a common complication of chronic kidney disease (CKD) beginning in childhood, with profound deleterious effects on quality of life, mental health, and social achievement. Despite optimal treatments of causative factors for growth retardation in children with CKD, more than 50% of patients reach end-stage renal failure with a height >2 SD below the mean, and most do not demonstrate "catch-up" growth after receiving a kidney transplant. Four decades ago, recombinant human growth hormone (rhGH) treatment was introduced after studies showed increased growth velocity and improved height SDS in uremic subjects. Since then, an abundance of published data showed significant improvements in health-related quality of life, and most studies revealed no significant adverse effects. Clinical practice guidelines recommended rhGH treatment in CKD Stages 3-5D and after transplantation. Despite these guidelines, this therapy remained underutilized. Most commonly cited barriers to the implementation of rhGH treatment were the need for daily injections, financial challenges, physicians' unfamiliarity with guidelines, and fear of adverse events.
CONCLUSIONS: rhGH has been shown to improve growth and final height in short children with CKD, with minimal adverse effects. Despite data of its successful use generated over 3 decades, this treatment is underutilized. More judicious utilization of the treatment should emphasize educating patients, their care givers, and members of the multidisciplinary treating team. Additional studies are needed to assess the longer-term rhGH treatment in larger cohorts of patients, leading to additional supportive data and clearer recommendations.
In addition to the standard physical therapy session, 30 patients in this group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
PURPOSE: To prepare a therapeutic agent useful for treating children's hyperkinetic disorders and containing 2-(4-methylaminobutoxy)diphenylmethane as an effective ingredient. CONSTITUTION: This therapeutic agent for hyperkinetic disorders contains a compound expressed by the formula, a hydrated derivative thereof or a salt thereof as an effective ingredient. The agent is formulated for a nonoral administation such as an injection, a drop, a suppository, an inhalant, a plaster, etc., by adding other usual additives if needed. The amount of an oral administration is 5-300mg/adult/day, preferably 150mg, from which the amount of the oral administration for children can be calculated. The administration can be made one to several times a day. An administration period can be suitably determined depending on the age of the child and the state of an improved symptom. The therapeutic agent expresses high effectiveness in the therapy of hyperkinetic disorders and the reduction of pathologic states and is highly safe with little adverse effects.  The therapeutic object of the hyperkinetic disorder is an attention disorder, an activity disorder and an impulsive abnormality, when one of those disorders is obviously observed on taking the age and the growth stage of a child into account in a family.
After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
The participants included in this study will be drawn from the Ingenix Normative Health Informatics Database, a proprietary research database containing claims and enrollment data dating back to 1993 for members of a large, geographically diverse US health plan. This study will include cohorts of participants who have claims consistent with a diagnosis of psoriasis and who initiate ustekinumab, anti-TNF biologics, non-anti-TNF biologics, or systemic non-biological treatments. Participants will be identified by claims bearing codes for dispensed drugs, procedures or diagnoses and followed after the launch of ustekinumab for up to 8 years. A sample of enrolled health plan members without claims evidence of diagnosis or treatment of psoriasis will also be selected. The claims database will be used to estimate the incidence of the primary outcomes of serious infections, tuberculosis (TB) and non-TB mycobacterial infections, malignancies such as lymphoma, and other selected outcomes. Potential cases of the study outcome identified through claims may be confirmed through medical record review. No study agents will be administered in this study. All patients will receive standard-of-care treatment as prescribed by their physician.
A semaglutide soluble microneedle composition and a preparation method therefor. The soluble microneedle composition comprises a needle body material and a base material. The needle body material comprises semaglutide and hyaluronidase, and the mass ratio of semaglutide to hyaluronidase is (0.05-172):1. The semaglutide and the hyaluronidase are combined to prepare the soluble microneedle composition, so that the semaglutide can be better promoted to diffuse into the systemic circulation. Compared with a semaglutide oral tablet, the soluble microneedle composition has the advantages that the blood sugar regulating effect is improved by nearly 40 times, the bioavailability of semaglutide is improved, and the dosage and the medication cost of the hypoglycemic drug are reduced. Moreover, a soluble microneedle technology is adopted, so that no pain is caused during use, and the discomfort of users is reduced.
Embodiments herein describe a wristband for securing a smart electronic wrist device to the human subject. A heart rate sensor, coupled to the wristband of one embodiment, attaches to the human subject, and to generate electronic signals responsive to the heart rate of the human subject. An analog to digital signal converting circuit (ADC), electronically coupled to the heart rate sensor, to receive electrical signals generated by the heart rate sensor. A digital signal encoding circuit, electronically coupled to the ADC, to convert the electrical signals to data signals. A wireless communication interface to transmit the digital signals wirelessly to a handheld phone call device. The handheld cellular device includes a physiological processor for analysis of the data signals concerning the heart rate of the human subject.
The invention relates to an avian influenza vaccine and a preparation method thereof, in particular to the preparation of a recombinant plasmid and a recombinant virus in the avian influenza vaccine preparation. The invention provides a recombinant gene and a preparation method thereof, and the recombinant gene is formed by fusing a baculovirus envelope protein gp64 signal peptide gene sequence, a major antigen gene HA sequence of an avian influenza virus and a baculovirus envelope protein gp64 transmembrane gene sequence. The invention further provides a recombinant plasmid that is constructed by recombining the recombinant gene and a pBacPAK8 plasmid, the recombinant bombyx mori baculovirus BmHA that contains the recombinant gene and a virus preparation method. The recombinant bombyx mori baculovirus BmHA that contains the recombinant gene is preserved in China General Microbiological Culture Center of Microbial Culture Collection Management Committee with the preservation number of CGMCC No.2316. The invention further provides an expression protein of the recombinant gene. The recombinant bombyx mori baculovirus BmHA and the protein that are provided by the invention can be used for preparing the avian influenza vaccine. The methods of the invention are applicable to large-scale production, and have lowered cost, high yield and large application value of the produced avian influenza vaccine.
Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
Against this background, WHO made it a high priority to provide fetal growth charts for estimated fetal weight and common ultrasound biometric measurements intended for worldwide use. WHO study was conducted in 10 countries including Egypt (Assiut).The study showed that fetal growth differs significantly between countries. Growth was to a small extent influenced by maternal age, height, weight, and parity, and by fetal sex. The study suggested that these WHO charts for growth are more suitable for international use than those commonly applied today. However, the differences between countries, with maternal factors, and with fetal sex mean that these growth charts may need to be adjusted for local clinical use to increase their diagnostic and predictive performance. In our setting, we are using the charts built in the ultrasound machines based on studies done in western countries. So, it is prudent now to implement the WHO fetal growth charts in our setting
Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
Novel, heterocyclic compounds having at least one ring nitrogen, disclosed side chains and, in some embodiments, an oxygen ortho to the ring nitrogen inhibit inflammatory responses associated with TNF-alpha and fibroblast proliferation in vivo and in vitro. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses in stimuli in vivo (particularly TN-alpha) are also described. The methods are expected to be of use in reducing inflammatory responses (for example, after angioplasty), in limiting fibrosis (for example, of the liver in cirrhosis), in inhibiting cell senescence, cell apoptosis and UV induced cutaneous immune suppression. Compounds having enhanced water solubility are also described.
BACKGROUND: Injury to saphenous nerve branches is frequent during knee surgery and can result in chronic pain. This saphenous neuralgia remains challenging to treat. Peripheral nerve stimulation (PNS) is a new potential non-pharmacologic treatment option. We present our outcomes experience using this technology in 12 patients.
METHODS: We retrospectively reviewed PNS placement for saphenous neuralgia between 2000 and 2022 at a single institution. Demographic information was collected as well as response to the device. Four-question short-form Patient-Reported Outcome Measurement Information System (PROMIS) Scores were collected before and 2 weeks, 6 weeks, and 6 months postprocedure. Specific scores included pain interference and behavior, functional mobility, depression, anxiety, and sleep impairment. Change in pain interference measured by the short-form PROMIS tool at 6 months was chosen as the primary outcome.
RESULTS: Twelve patients met inclusion criteria, with 10 patients having the full 6-month follow-up. In these 10 patients, the mean change from baseline in the short-form adjusted pain interference score (greater difference means improved pain) at 6 months was 5.8 (SD 6.5). Among all patients, average follow-up was 11.5 months (range 3-35 months). Most patients' symptoms developed after knee surgery (84%). Prior to PNS, patients underwent other treatments including cryoablation (8%), radiofrequency ablation (16%), saphenous neurectomy (16%), or surgical release of adjacent nerves (25%). Ten patients (83%) reported any improvement in symptoms while two reported no benefit. Complications occurred in four patients (33%). Two patients had the device removed and a third discontinued use. PROMIS Scores for pain, functional mobility, mood, and sleep impairment all improved.
DISCUSSION: Limited effective treatments exist for saphenous neuralgia. Our case series demonstrates the potential of PNS as a treatment for saphenous neuralgia. Comparative effectiveness studies are warranted to assess whether our effect size is clinically relevant.
The method for preparing bicyclic heterocyclic ring compds. for calcium independent cAMP phosphodiesterase inhibitor antidepressant is presented.  In the process, bicyclic[2.2.1  hept-2-yl ether 0.014 mole was dissolved in 50ml of ethanol, and then added with 0.736g of sodium cyanatc and 1.0g of methyl amine HCl.  The above mixture soln. is stirred for 18hrs at room temp. and reacting soln. is diluted with saturated sodium bicarbonate soln. and extracted with 30ml of ethylether three times.  The obtained organic layer is washed with 30ml of saturated sodium chloride solution and dried with anhydrous sodium sulphate.
This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favorable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favorable change or starts to show an unfavorable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
FIELD: medicine. SUBSTANCE: the method deals with preventing undesirable pregnancy by intravaginal injecting efficient quantity of composition containing narrow- or monodisperse condensation polymer of aromatic sulfoacid and aldehyde, or its pharmaceutically acceptable salt. Moreover, it, also, deals with preventing undesirable pregnancy including vaginal introduction of gel containing the above-described condensation polymer. The innovation in question enables to apply the abovementioned compounds in manufacturing medicinal product to avoid pregnancy, or contraceptive preparation. By the present innovation these compounds either stimulate vagina poorly or do not stimulate it at all. EFFECT: higher efficiency. 9 cl, 27 ex, 2 tbl
Control group participants will receive no intervention. They will be thanked for taking part in the study, advised that they may want to lose weight on their own and reminded of the next assessment at 12 weeks. The investigators will explain the value of control groups in randomised trials and the impact that remaining in follow-up has for the impact of the trial. They will also be reminded that they will receive equal financial reimbursement.
Graft primary dysfunction (PDF) after liver transplantation is enhanced by the increasing use of extended-criteria allografts. This complication is burdened with high mortality and morbidity rates among liver transplant recipients. Alpha-GST is a short-life hepatocyte enzyme that may be an interesting biomarker for liver injury. A recently developped ELISA technique may allow fast and easy measurement of alpha-GST plasma concentration (Fastpack IP α-GST Immunoassay, Qualigen Inc., Carlsbad, CA). This study aims to evaluate the ability of plasma alpha-GST measurements in liver donor to predict PDF in liver recipient. Methods: Observational study conducted in one center (Beaujon hospital, APHP, Clichy, France). Measurements of plasma levels of alpha-GST using Fastpack IP α-GST Immunoassay (Qualigen Inc., Carlsbad, CA) at the time of organ removal in liver donor and daily from day 0 to day 7 after liver transplantation in recipients.